anti-Francisella tularensis, LPS antibody product blog
Tags: Antibody; Monoclonal Antibody; Francisella tularensis, LPS; anti-Francisella tularensis, LPS antibody;
The Francisella tularensis, LPS n/a (Catalog #MBS631733) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s Francisella tularensis, LPS can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA), Immunofluorescence (IF).Suitable for use in Immunofluorescence and ELISA.
Dilution: Immunofluorescence: 1:10-1:50
ELISA: 1:20-1:200. Researchers should empirically determine the suitability of the Francisella tularensis, LPS n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Francisella tularensis is a small, nonmotile, aerobic, gram-negative coccobacillus. It has a thin lipopolysaccharide-containing envelope and is a hardy non-spore-forming organism that survives for weeks at low temperatures in water, moist soil, hay, straw, and decaying animal carcasses. Lipopolysaccaride (LPS) is a main species-specific antigen of Francisella tularensis. According to the data available LPS of tularemia microbe differs from LPS of other gram-negative bacteria. LPS of tularemia microbe hasn\'t yet revealed the properties of classical endotoxin, which may be connected with non-typical structure of lipid A, a toxic component of LPS.
In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing Francisella tularensis, LPS are readily searchable from our website. Different antibodies against the same target such as Francisella tularensis, LPS may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.